BioSpace News Archive

Locanabio, Inc. announced the first presentation of data from its next generation engineered small nuclear RNA, or snRNA, platform, which is designed to efficiently deliver targeted snRNA payloads via an adeno-associated virus for long-term therapeutic expression.

Daré Bioscience, Inc. (NASDAQ: DARE) and Strategic Science & Technologies, LLC (SST) today announced initiation of screening and enrollment for a Phase 1 clinical study using thermography to assess the pharmacodynamic and pharmacokinetic characterization of Sildenafil Cream, 3.6% (Sildenafil Cream), a late-stage product candidate being developed as a potential new treatment for female sexual arousal disorder (FSAD).

Novartis announced new long-term data from the ALITHIOS open-label extension study showing that up to five years, patients treated earlier and continuously with Kesimpta® had fewer disability worsening events and low brain volume change versus those who started on teriflunomide and were later switched to Kesimpta.

Hansa Biopharma, the pioneer in immunomodulatory enzyme technology for rare IgG mediated diseases, announced its business update and interim report for January to March 2023.

BioInvent International AB announces that a fourth complete response has been observed in the 100 mg dose expansion cohort in the IV arm of the Phase 1/2 trial of its lead drug candidate BI-1206, the novel anti-FcgRIIB antibody, in combination with rituximab in non-Hodgkin’s lymphoma.

Immunovia announced it will participate in a webinar titled “Biomarkers and Liquid Biopsy for Early Detection of Pancreatic Cancer” hosted by the National Pancreas Foundation on April 26, 2023, at 7:00 pm ET.

Dermata Therapeutics, Inc. announced that it has received a response from the U.S. Food and Drug Administration to the Company’s Type C Chemistry, Manufacturing, and Controls meeting request.

Teleflex Incorporated (NYSE:TFX) will host a conference call to discuss its first quarter financial results and provide an operational update at 8:00 a.m. Eastern Time on Thursday, May 4, 2023.

Augmedix Inc. today announced that it has executed a strategic financing with HCA Healthcare, Inc. (NYSE: HCA), one of the nation’s leading healthcare providers, and Redmile Group, LLC, a San Francisco-based institutional healthcare investor.

Augmedix today announced a partnership with HCA Healthcare, Inc. (NYSE: HCA), one of the nation’s leading healthcare providers, to accelerate development of technology that aims to transform the way patient care is documented in the acute care setting.